The contribution of aberrant methylation alterations of BMP6, BRCA1 and P16 genes in lymph node metastasis might provide a further clue to establish useful biomarkers for screening metastasis. This evidence concerns the gene CDKN2A and metastatic malignant neoplasm in the lymph nodes.